In this study, the investigators will explore our protein-based platform assessing commensals potentially contributing to features of CD, while assessing the global composition and abundance of AMPs expressed in the GI tract under specific CD-relevant clinical contexts. This would enable us to (a) identify new commensals contributing to features of CD spectrum and various sub-types; (b) uncover the mechanistic basis of dysbiosis in CD (c) utilize the pipeline to develop new theranostic for disease exacerbation, complication and treatment responses; and (d) potentially enable future exploitation of novel AMP combinations, and their respective antimicrobial capacity to counteract dysbiosis in CD.
Uncovering the proteomic manifestations of perturbed host-microbiome communications in CD will eventually enable the development and validation of clinical non-invasive surrogate markers, mechanistically determine causative drivers of CD, and potentially facilitate the development of novel therapeutic interventions.
Age ≥ 18
Candidates for a medically-indicated, diagnostic colonoscopy due to suspected new-onset CD.
Naïve to any medical or nutritional intervention.
Established diagnosis of inflammatory bowel disease (IBD) with prior treatment.
Chronic gastro-intestinal disorder (e.g. celiac disease, eosinophilic esophagitis, collagenous gastritis, autoimmune gastritis, etc.).
Type 1 or type 2 diabetes mellitus.
Past or present history of malignancy.
Weizmann Institute of Science
Lead sponsor
HaEmek Medical Center, Israel
Collaborator